Published in Cancer Weekly, May 14th, 2002
Patients in the Arimidex treatment arm had a 58% lower risk of developing a contralateral breast tumor compared with those taking tamoxifen (OR=3D0.42, p=3D0.0068). Furthermore, in postmenopausal women with receptor-positive breast tumors, Arimidex was shown to lower the risk of contralateral breast cancer by 64%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.